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ABSTRACT
Recent clinical data indicate a synergistic therapeutic effect between trastuzumab 
and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In 
HER2+ BC experimental models and patients, we investigated whether this synergy 
depends on the ability of drug-induced stress to improve NK cell effectiveness and 
thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated 
with docetaxel showed up-modulation of NK activator ligands both in vitro and in 
vivo, accompanied by a 15–40% increase in in vitro trastuzumab-mediated ADCC; 
antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D 
receptor expression was increased by docetaxel treatment in circulating and splenic 
NK cells from mice xenografted with tumor cells, an increase related to expansion 
of the CD11b+Ly6G+ cell population. Accordingly, NK cells derived from HER2+ BC 
patients after treatment with taxane-containing therapy expressed higher levels of 
NKG2D receptor than before treatment. Moreover, plasma obtained from these patients 
recapitulated the modulation of NKG2D on healthy donors’ NK cells, improving their 
trastuzumab-mediated activity in vitro. This enhancement occurred mainly using 
plasma from patients with low NKG2D basal expression. Our results indicate that 
taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and 
suggest that taxanes concomitantly administered with trastuzumab could maximize the 
antibody effect, especially in patients with low basal immune effector cytotoxic activity.
INTRODUCTION
Trastuzumab, a recombinant humanized monoclonal 
antibody directed to the extracellular domain of the 
HER2 protein, is the paradigm of tailored treatment for 
patients with HER2-positive breast cancer. Recent clinical 
data indicated a synergistic therapeutic effect between 
trastuzumab and chemotherapy in the neoadjuvant setting 
in these patients, with up to 70% pathological complete 
response [1] and especially when taxanes are used [2;3]. 
Moreover, data from the NCCTG N9831 trial suggest that 
trastuzumab is more effective if used concurrently with 
rather than following the taxane component of adjuvant 
chemotherapy [4]. However, the mechanism(s) underlying 
this synergy remains unclear, prompting investigations 
to further define trastuzumab killing activity when 
administered with chemotherapy.
Several preclinical studies have indicated that 
trastuzumab anti-tumor activity depends on several direct 
or indirect cytostatic and cytotoxic activities [5;6]. The 
Oncotarget256www.impactjournals.com/oncotarget
importance of immune cells in trastuzumab therapy is 
supported by studies showing that ADCC contributes 
mainly to the antitumor effects of trastuzumab in HER2-
positive tumors in mice [7] and in breast carcinoma pre-
operative clinical studies, in which it was associated with 
increased tumor infiltration of natural killer (NK) cells 
[8;9]. NK cells play a key role in trastuzumab-mediated 
ADCC [10] and, if stimulated, enhance trastuzumab 
efficacy [11]. The NK cell detection system, in addition 
to the low-affinity Fc receptor CD16, which permits 
NK cells to kill antibody-coated target cells, includes a 
variety of cell surface activating and inhibitory receptors, 
the engagement of which by ligands expressed on tumor 
cells regulates immune effector cell activities. A key 
receptor for NK cell activation is NK Group 2 member 
D (NKG2D), a type II transmembrane C-type lectin-
like receptor expressed on all NK cells. It binds multiple 
ligands, including MHC class I chain-related A (MICA), 
MICB and several UL-16 binding proteins (ULBPs), 
which are induced after cellular stress [12] and are the 
most common ligands for NK cell receptors in breast 
carcinomas together with DNAM-1 ligands [13].
In this study, we investigated in HER2-positive 
breast carcinoma models the effect of taxane treatment 
on expression levels of ADCC-associated factors with 
a focus on NKG2D ligands, and correlated the changes 
in these molecules with the ability of trastuzumab to 
mediate ADCC. Moreover, we investigated the effect of 
chemotherapy on NK cells in xenografted mice and in 
HER2-positive breast carcinoma patients treated with 
neoadjuvant therapy.
RESULTS
Modulation of NKG2D ligand cell surface 
expression in response to docetaxel
To investigate whether docetaxel upregulates the 
production of the NK cell stimulatory ligands MICA, 
MICB, ULBP1 and ULBP2 of the NKG2D receptor, 
HER2-overexpressing human breast carcinoma cell lines 
BT474 and MDAMB361 were treated in vitro for different 
times with 100 nM docetaxel and analyzed by flow 
cytometry. Docetaxel-treated cells revealed a significant 
increase in membrane-associated ligand expression as a 
rapid and dynamic event, with the greatest enhancement 
within 6–12 hours and a return to basal levels within 24–
48 hours (Figure 1A, 1B). Longer drug treatment increased 
the soluble forms of MICA and ULBP2, the two molecules 
reportedly cleaved and released into the extracellular 
space as negative feedback ligand-mediated NK regulation 
[14], in culture medium of breast carcinoma cells at 48 and 
72 hours after docetaxel treatment compared to untreated 
cells (Supplementary Figure S1), partly explaining their 
reduction on the cell membrane. Specifically, soluble 
ULBP2 amounts increased in both cell lines as compared 
to untreated cells. Similar results were obtained for soluble 
MICA in BT474 but not in MDAMB361 culture medium, 
where soluble MICA was never detectable.
To test whether NK cell stimulatory ligands are also 
up-modulated by docetaxel in vivo, SCID mice bearing 
MDAMB361 tumors in the mammary fat pad were treated 
intravenously with 20 mg/Kg docetaxel or not treated and 
analyzed 24 hours later for expression of MICA and ULBP2 
by Western blotting on cells obtained from disaggregated 
tumors. Levels of MICA ligand were significantly higher in 
tumors derived from docetaxel-treated than untreated mice 
(Figure 1C and Supplementary Figure S2).
NKG2D ligand expression and susceptibility to 
trastuzumab-mediated ADCC
To test whether increased expression of NKG2D 
ligands observed on breast carcinoma cells after treatment 
with docetaxel enhances trastuzumab-mediated cell 
cytotoxity, tumor cells were analyzed in 51Cr-release assays 
using human PBMCs from healthy donors as effector 
cells. Docetaxel treatment for 6 hours rendered BT474 and 
MDAMB361 target cells more sensitive to trastuzumab-
dependent ADCC, with an average killing increase of 38% 
in BT474 (Figure 2A) and 14% in MDAMB361 (Figure 2B) 
cells. This ADCC increment was significantly inhibited in 
both cell lines by antibo dies blocking the NKG2D receptor 
(Figure 2C, 2D), supporting the role of the NKG2D ligand-
receptor interaction in increasing trastuzumab-mediated 
ADCC upon chemotherapy. Comparable results were 
obtained in BT474 target cells treated with docetaxel for 12 
hours, whereas a trend toward inhibition of trastuzumab-
mediated killing was found in BT474 and MDAMB361 
cells treated with docetaxel for 72 hours as compared 
with untreated controls (Supplementary Figure S3), when 
NKG2D ligand expression was lower in treated than in 
untreated cells (Figure 1).
To further demonstrate the direct role of NKG2D 
in trastuzumab-mediated ADCC of HER2 positive breast 
carcinoma cells, PBMCs from healthy donors were 
collected, treated with prostaglandin-E2 (PGE2) for 
24 hours to force NKG2D down-modulation [13], and 
used in ADCC assay against BT474 cells. The induced 
reduction of NKG2D expression on NK cells (Figure 2E) 
led to a reduced killing of BT474 cells in the presence of 
trastuzumab compared to untreated PBMCs (Figure 2F).
Increased expression of NKG2D in circulating 
NK cells in mice receiving chemotherapy
The activity of docetaxel on effector cells was 
analyzed by comparing the phenotype of NK cells 
obtained from MDAMB361 tumor-bearing mice with 
that of tumor-free mice upon docetaxel treatment. No 
differences in NKG2D expression on NK cells were 
observed at 24 hours after treatment (not shown), whereas 
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NKG2D expression was significantly higher in NK cells 
derived from chemotherapy-treated than saline-treated 
tumor-bearing mice 6 days after treatment (Figure 3A). 
Chemotherapy treatment impaired the proportion of NK 
cells only in tumor-bearing mice (Figure 3B). Notably, 
NKG2D expression did not differ in NK cells derived from 
tumor-free mice irrespective of treatment, suggesting that 
the presence of the tumor is necessary for up-modulation 
of NKG2D levels in NK cells upon chemotherapy.
To determine whether the increase in NKG2D 
was directly induced by tumor cells after treatment with 
chemotherapy, PBMCs obtained from healthy donors 
were cultured with supernatants conditioned by BT474 
cells treated or not with docetaxel. No modulation of 
NKG2D expression was found in NK cells conditioned 
by supernatant of BT474 cells treated or not with 
docetaxel (Figure 3C) or co-cultured for 24 hours with 
BT474 cells in the presence or absence of docetaxel 
(Figure 3D). Similar results were observed in NK cells 
after 48 hours of co-culture (data not shown). These data 
suggest that docetaxel-induced up-modulation of the 
NKG2D receptor observed in mice is not directly affected 
by tumor cells after treatment with chemotherapy, but is 
likely mediated through their interaction with the host 
microenvironment.
Based on the reported accumulation of myeloid 
cells in tumor-bearing mice and in cancer patients 
[15], we investigated the expansion of these cells in 
the spleen of mice injected with MDAMB361 cells and 
treated with docetaxel or untreated. Docetaxel treatment 
led to an increase in the number of CD11b+Ly6G+ 
cells (granulocytic myeloid cells) as compared to the 
number in untreated mice (Figure 4A), whereas similar 
numbers of CD11b+Ly6C+ cells (monocytic myeloid 
cells) were found in mice irrespective of treatment 
(Figure 4B). The percentage of CD49+ cells (NK cells) 
and the NKG2D expression on NK cells were lower 
and higher, respectively, in treated than in untreated 
mice both in blood (Supplementary Figure S4) and in 
the spleen (Figure 4C, 4D), raising the possibility that 
NKG2D expression in chemotherapy-treated mice is 
modulated by an increase in granulocytic myeloid cells 
that expand only in the presence of tumors. Analysis 
of purified myeloid cells (GR1+) from mice treated or 
not with docetaxel and co-cultured at a 1:1 ratio with 
splenocytes derived from tumor-free mice indicated that 
NKG2D relative expression on NK cells was increased, 
irrespective of docetaxel treatment of mice from which 
they were purified (Figure 4E). Thus, the higher number 
of myeloid cells found in mice treated with docetaxel 
than in untreated mice might explain the increased 
NKG2D expression on NK cells.
Increased expression of NKG2D in circulating 
NK cells of patients receiving chemotherapy
Based on the results obtained in preclinical models, 
we investigated the NK cell phenotype in patients with 
HER2-positive breast carcinomas treated with neoadjuvant 
chemotherapy and trastuzumab. Analysis of the NK 
phenotype in PBMCs obtained from 9 patients before 
(pre) and after (post) the first chemotherapy treatment 
cycle (4 cycles of taxane-based chemotherapy) showed 
that treatment slightly impaired NK cell proportions 
(Figure 5A), in particular CD16+ NK cells (Figure 5B), but 
significantly increased NKG2D expression on NK cells 
(Figure 5C). Note that other natural cytotoxicity receptors 
involved in human NK activity (i.e., NKp30, NKp44 and 
NKp46) were not significantly modified by chemotherapy 
(Supplementary Figure S5). Thus, chemotherapy appears 
to change the NK cell surface receptor configuration in 
patients with HER2-positive breast carcinomas. Moreover, 
healthy donor PBMCs cultured for 24 hours with plasma 
obtained from patients post-treatment showed significant 
up-modulation of NKG2D on NK cells compared to 
plasma collected pre-treatment (Figure 5D), indicating 
that the plasma treatment recapitulated the drug-induced 
up-modulation of NKG2D on NK cells.
Figure 1: Modulation of NKG2D ligands on breast carcinoma cells in response to docetaxel treatment. A, B. BT474 (A) 
and MDAMB361 (B) cells were treated with 100 nM docetaxel for the indicated times and analyzed by flow cytometry. Shown are fold-
increases of ligand expression in treated versus untreated cells at the same time points. Data are mean ± SEM (n = 3). C. Fold-increase 
in MICA and ULBP2 protein expression levels, as assessed by Western blot and quantified by densitometric analysis using Quantity One 
software, in MDAMB361 breast carcinoma cells grown in SCID mice and treated with 20 mg/Kg docetaxel versus untreated tumors. Data 
are mean ± SEM (n = 5). *p < 0.05 by paired Student’s t-test.
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Increased expression of NKG2D in patients and 
trastuzumab-mediated ADCC
To determine whether enhanced NKG2D 
expression after chemotherapy is associated with 
improved NK cell function in the context of breast 
cancer, PBMCs obtained from healthy donors were 
treated with plasma from patients and used in ADCC 
assay. Treatment of PBMCs from healthy donors with 
pre-treatment plasma from different patients induced 
different ADCC ability of the same PBMC (Figure 
6A), and the mean cytotoxic activity of effector cells 
correlated with NKG2D expression evaluated on NK 
cells (r = 0.86, p = 0.06). Interestingly, the lower the 
PBMC lytic activity induced by pre-treatment plasma, 
the higher the fold-increase in PBMC ADCC activity 
induced by post-treatment versus pre-treatment 
plasma (Figure 6A and Supplementary Figure S6). 
Indeed, treatment of PBMCs from healthy donors 
with patient P1 post-treatment plasma, which induced 
the highest expression of NKG2D on NK cells and, in 
turn, the highest trastuzumab-mediated ADCC before 
chemotherapy, did not induce a significant increment in 
trastuzumab-mediated ADCC compared to pre-treatment 
plasma (Figure 6B). By contrast, post-treatment plasma 
derived from patient P5 induced an increment in NKG2D 
expression and consequently of ADCC compared to the 
corresponding pre-treatment plasma (Figure 6B), which 
had the lowest basal activity (Figure 6A). Notably, the 
trastuzumab-mediated ADCC induced by NK cells after 
treatment with P5 post-treatment plasma increased 
to levels similar to those obtained with NK cells after 
P1 pre-treatment plasma (Figure 6B). These data 
suggest that the benefit of chemotherapy in improving 
trastuzumab-mediated ADCC occurs mainly in patients 
with low basal cytotoxic activity of immune effector 
cells, and that addition of chemotherapy to antibody 
administration may not be as relevant in improving 
trastuzumab activity for patients with elevated basal 
lytic activity of effector cells. Consistent with this view, 
NKG2D basal expression in a new series of 18 HER2-
positive breast cancer patients before neoadjuvant 
treatment with one cycle of trastuzumab alone [16] and 
analyzed by qPCR using RNA obtained from the buffy-
coat of collected blood was higher in tumors that benefit 
from the antibody, evaluated as at least 20% reduction 
in the standardized uptake value evaluated by FDG PET/
CT scan (Figure 6C), than in non-responsive tumors (p 
= 0.0249). Moreover, patients that reached a pCR at 
the end of the neoadjuvant treatment with trastuzumab 
and docetaxel showed higher basal NKG2D expression 
than did partial responders with borderline statistical 
significance (Figure 6D, p = 0.0806); the two patients of 
the INT cohort with the highest NKG2D were those with 
Figure 2: Docetaxel treatment increases trastuzumab-mediated cell cytotoxicity on tumor cells, as assessed by 51Cr 
release. A, B. To evaluate ADCC, 51Cr-labeled breast cancer cell lines BT474 (A) and MDAMB361 (B) were treated for 6 hours with 100 
nM docetaxel (DTX) or not treated (NT) and cultured for 4 hours with PBMCs from healthy donor blood samples in medium containing 
trastuzumab (4 μg/ml). Shown are percentages of lysis of target cells at 50:1 effector:target cell ratio of PBMCs from independent healthy 
donors (A: n = 19, p = 0.0004; B: n = 13, p = 0.0006). C, D. BT474 and MDAMB361 cells, respectively, treated with DTX or not treated 
were cultured as above with PBMCs pre-incubated for 30 minutes with blocking NKG2D blocking antibodies (1 μg/ml). Values are median, 
interquartile range (box), minimum and maximum. (C: n = 6; D: n = 6). E, F. PBMCs from independent healthy donors (n = 4) were treated 
with 100 nM PGE2 for 24 hours, analyzed by flow cytometry for NKG2D expression (MFI on NK cells, E) and used in ADCC assay (F) 
against BT474 cells as described above. *p < 0.05, **p < 0.01, ***p < 0.001 by paired Student’s t-test.
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a pCR after chemotherapy and trastuzumab treatment (p 
= 0.0142).
DISCUSSION
In the present study, we report for the first time that 
taxanes significantly increase NKG2D ligand expression on 
tumor cells and their susceptibility to NK activity. Moreover, 
docetaxel induces the expression of the activating cognate 
receptor NKG2D on NK cells, increasing their cytotoxic 
activity mediated by trastuzumab.
The up-modulation of NKG2D ligands by 
chemotherapy is consistent with the function of these 
ligands, whose expression is generally linked to cellular 
stress mechanisms that induce danger signals [17]. Based 
on the demonstrated role of NKG2D signals in inducing NK 
activation favoring NK degranulation rather than adhesion 
to tumor cells [18] during ADCC, the induced trastuzumab 
activity after chemotherapy treatment observed in our model 
is likely due to the interaction between NKG2D ligands with 
their receptor, as supported by the ability of anti-NKG2D 
receptor antibodies to abrogate the chemotherapy-induced 
increase of in vitro trastuzumab-dependent ADCC. The 
involvement of the NKG2D ligand/receptor interaction in 
increasing trastuzumab-mediated ADCC observed here is 
in agreement with the increased activity of an anti-ERBB2-
NKG2D ligand fusion protein targeting HER2 tumors and 
triggering lymphocytes that express the NKG2D receptor 
compared to anti-HER2 antibody alone in preclinical models 
[19].
Since chemotherapy is known to cause bone marrow 
suppression that manifests as reduced numbers of peripheral 
blood immune cells [20], we also evaluated its effect on 
ADCC effector cells. Although the percentage of NK cells 
was slightly reduced by chemotherapy, NKG2D expression 
on NK cells was increased after docetaxel treatment. 
While NKG2D up-modulation upon drug treatment was 
strictly dependent on the presence of tumor cells in mice, 
such cells do not appear to play a direct role in enhancing 
NKG2D expression, since no direct modulation of NKG2D 
on NK cells was observed by co-culturing PBMCs 
with tumor cells according to treatment with docetaxel. 
However, we did found that NKG2D up-modulation on 
NK cells after chemotherapy treatment involves the host 
microenvironment, specifically granulocytic myeloid cells, 
as indicated by the increase of NKG2D on NK cells after 
co-culture of GR1+CD11b+ cells with splenocytes derived 
from healthy mice. Indeed, neutrophils have been reported 
Figure 3: Chemotherapy alters NKG2D expression in circulating NK cells in mice injected with tumor cells. A, B. 
SCID mice were xenotransplanted with MDAMB361 breast carcinoma cells and, when tumors reached a volume of 150 mm3, treated with 
20 mg/Kg docetaxel (DTX) or not treated. Six days after treatment, NKG2D expression  (MFI of NK cells, A) and NK cell proportions 
(B) were analyzed in mouse blood. The same analysis was performed in tumor-free SCID mice of the same age (A, B) *p < 0.05 by unpaired 
Student’s t-test. C, D. PBMCs from independent healthy donors were cultured for 24 hours in medium conditioned or not by BT474 breast 
carcinoma cells (C) or with BT474 cells treated or not with docetaxel (D) and analyzed for NKG2D expression (MFI of NK cells) by flow 
cytometry. *p < 0.05 by paired Student’s t-test.
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Figure 4: Chemotherapy alters NKG2D expression of NK cells through myeloid cells. A, B, C, D. Mice bearing MDAMB361 
tumors were treated with docetaxel (DTX) and 6 days later, spleens were analyzed for NK and myeloid cell expansion. CD11b+Ly6G+ 
(A) CD11b+Ly6C+ (B) NK (CD49b+) cells (C) and NKG2D expression (MFI of NK cells, D) were analyzed by flow cytometry. E. 
Splenocytes from tumor-free SCID mice were co-cultured or not with purified GR1+ myeloid cells for 24 hours and analyzed for NKG2D 
expression by flow cytometry (n = 6). *p < 0.05, **p < 0.01 by unpaired Student’s t-test.
Figure 5: Chemotherapy alters the NK cell phenotype in human patients. A, B, C. PBMCs isolated from patients at different 
time points during neoadjuvant treatment (pre: before any treatment, post: after chemotherapy) were analyzed by flow cytometry. The 
percentage of NK cells, identified as CD3– CD56+ (A) and their proportion of CD16+ (B) and the NKG2D expression (C) are shown. 
D. NKG2D expression on NK cells (CD3- CD56+ CD16+) of PBMCs from independent healthy donors treated in vitro with plasma derived 
from patients pre and post treatment. **p < 0.01, ***p < 0.001 by paired Student’s t-test.
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to play a role in regulating differentiation and activation 
of NK cells [21]. Moreover, the selective expansion of 
CD11b+Ly6G+and the increase in NKG2D expression 
on NK cells in our models upon docetaxel treatment is 
consistent with the elevation of granulocytic myeloid 
cells after chemotherapy in patients [22], and with the 
increase in GM-CSF and IL6 production, that supports 
myeloid cell expansion, as well as the increased NK cell 
cytotoxic activity demonstrated upon taxane treatment 
in human patients [23]. We speculate that tumor cells 
after chemotherapy treatment modulate the production 
of soluble factors that induce expansion of myeloid cells 
[24;25], as we observed in breast cancer cell lines in vitro 
after chemotherapy treatment (not shown). Myeloid cells, 
in turn, could sense chemotherapy and increase expression 
of NKG2D ligands described to induce NK activity when 
expressed on myeloid cells [26]. Because docetaxel is also 
able to induce NKG2D ligand expression in tumor cells, 
the interaction between tumor NKG2D ligands and NKG2D 
receptor expressed by NK cells significantly improves 
trastuzumab-mediated ADCC. Although the modulation 
of the NKG2D ligand/receptor could be coincidental, 
our findings open the door to further research aimed at 
harnessing the power of the modulation of both elements 
for improving therapy. Moreover, our results obtained 
regarding NKG2D raise the possibility that other activating 
receptors and co-regulators such as DNAM-1, described to 
be involved in breast cancer-NK cell recognition [13], are 
involved in increasing trastuzumab activity in humans and 
await further investigation.
Our data obtained in experimental models support 
the notion that chemotherapy causes modifications 
important for inducing an increase in trastuzumab-
mediated cytotoxicity and consequent response of 
patients to treatment. Thus, while trastuzumab might also 
augment chemotherapy-induced tumor toxicity, causing 
attenuation of DNA repair activity and increasing 
apoptosis [27], our results strongly suggest that the 
Figure 6: Expression of NKG2D in patients is associated with trastuzumab-mediated ADCC. A. Trastuzumab-mediated 
lysis of 51Cr-labeled BT474 cells induced by healthy donor PBMCs (n = 4) treated with plasma obtained from 5 patients (P1-P5) before 
docetaxel administration. Data are mean and range. ADCC post > pre refers to the percentage of times that PBMCs treated with post-
treatment plasma induced greater trastuzumab-mediated ADCC of BT474 cells than when treated with the pre-treatment plasma. B. ADCC 
of BT474 cells induced by PBMCs obtained from healthy donors treated with pre- and post-treatment plasma of patients P1 and P5 (n 
= 7). *p < 0.05, **p < 0.01 by paired Student’s t-test. C, D. NKG2D expression as evaluated by qPCR using RNA obtained from the blood 
buffy-coat of 18 HER2-positive breast cancer patients before any treatment according to response to one cycle of trastuzumab alone (C) 
and according to pCR (D) RD: residual disease. *p < 0.05 by unpaired Student’s t-test.
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reported synergy between trastuzumab and docetaxel 
in HER2-positive breast cancer patients and in nude 
mice bearing HER2-expressing tumors and treated with 
the two drugs in combination [27;28] depends on the 
increased ADCC rather than on the inhibition of HER2-
mediated DNA repair by the antibody. Indeed, taxanes, 
drugs that showed the best therapeutic effect when 
combined with trastuzumab [2;29], presumably act as 
inhibitors of microtubules rather than as intercalants of 
the DNA and are thus unlikely to promote DNA repair 
mechanisms involving HER2. However, since recent 
evidence suggests that taxane can also induce breaks 
in single-strand DNA [30], it is possible that such a 
mechanism also contributes to the synergy between 
trastuzumab and taxane. The up-modulation of NKG2D 
in NK cells of breast carcinoma patients after treatment 
with taxane-containing chemotherapy further supports 
the relevance of drug treatment in improving the ability 
of trastuzumab to trigger host immune effectors against 
tumor cells. Thus, the evidence that taxanes significantly 
increase tumor susceptibility to NK activity provides an 
avenue to improving the cytotoxic effect of trastuzumab 
by injecting the antibody concomitantly with taxanes in 
a neo-adjuvant setting. Such a protocol could also reduce 
the duration of therapy.
Although based on a small subset of patients, our 
data suggest that the benefit of taxanes in improving 
trastuzumab-mediated ADCC occurs mainly in patients 
with low basal cytotoxic activity of their immune 
effector cells and with potentially low responsiveness 
to trastuzumab-mediated ADCC. Indeed, the meager 
enhancement of NKG2D after chemotherapy recorded 
in women with elevated basal NKG2D expression does 
not appear to support the relevance of chemotherapy in 
improving trastuzumab activity in patients with innate 
high lytic activity of effector cells, consistent with results 
obtained in the TRUP cohort that showed high expression 
levels of NKG2D on NK cells from patients responsive to 
one cycle of trastuzumab alone. Since patients with high 
NKG2D expression on NK cells before any treatment are 
also those who reached a pCR in the TRUP and the INT 
cohorts, it remains to be determined whether trastuzumab 
alone might be sufficient for a pCR in such patients or 
whether the addition of chemotherapy is always necessary 
to generate a long-lasting response. In this context, the 
validation of NKG2D expression levels on circulating NK 
cells from patients before any treatment as a predictive 
marker of trastuzumab response could represent a simple 
tool for the selection of patients who will benefit from the 
addition of taxanes to antibody administration.
The relevance of circulating NKG2D-positive NK 
cells as indicators of antibody therapy success is strengthened 
by results of Fisher and coworkers [31], who showed that 
circulating NK cells able to mediate ADCC specifically 
express NKG2D, but not NKp30 or NKp46 activating 
receptors. Activated NK cells are known to shape the 
adaptive immune response [32;33], described to be crucial for 
the complete eradication of BC upon trastuzumab treatment 
both in preclinical [34;35] and clinical samples [36;37]. 
Differences in the patients’ adaptive immunity activation 
or recruitment could explain the variable clinical response 
of patients observed after treatment with trastuzumab 
and chemotherapy, despite the modulation of NKG2D by 
chemotherapy observed in all treated patients.
Together, our data indicate that the synergy between 
taxanes and trastuzumab occurs mainly through the NKG2D 
ligand/receptor-mediated activation of NK cells and mainly 
in those patients with low NKG2D expression on effector 
cells at the time of diagnosis. The understanding of the 
mechanism through which NKG2D levels on NK cells 
are increased promises to help in improving trastuzumab 
activity through immunotherapy combinations for those 
patients who do not respond to treatment.
MATERIALS AND METHODS
Cell lines and treatments
Human HER2-positive breast carcinoma cell 
lines MDAMB361 and BT474 (American Type Culture 
Collection) were authenticated using the Short Tandem 
Repeat Profiling method in our Institute facility and 
maintained in appropriate medium supplemented with 10% 
(v/v) FBS (Thermo Scientific, Waltham, MA, USA) and 
L-glutamine in a 5% CO2 humidified chamber at 37°C. Cells 
were treated in complete medium with 100 nM docetaxel 
(DOCETAXEL, Sanofi Aventis) for different times.
Mice and treatments
Six- to 8-week-old SCID mice (Charles River, Calco, 
Italy) were maintained in laminar-flow rooms at constant 
temperature and humidity, with food and water given ad 
libitum. Mice were injected into the mammary fat pad with 
5x106 MDAMB361 cells in growth medium diluted 1:1 with 
Matrigel (BD Bioscience, San Jose, CA, USA). Experimental 
protocols used for animal studies were approved by the Ethics 
Committee for Animal Experimentation of Fondazione 
IRCCS Istituto Nazionale dei tumori of Milan in accordance 
with institutional guidelines.
Docetaxel was administered (20 mg/Kg) 
intravenously. Spleen and blood were collected from mice 
after treatment, and single-cell suspensions obtained after 
lysis of red blood cells were analyzed by flow cytometry. 
Myeloid cells were purified from total splenocytes using 
biotinylated anti-GR1 antibody (Miltenyi Biotec, San 
Diego, CA, USA) as described [38].
Patients
Breast carcinoma core biopsies were obtained 
from 8 patients (INT cohort) before a treatment protocol 
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consisting of 3 or 4 cycles of AT (adriamycin plus taxotere) 
followed by 4 cycles of CMF (cyclophosphamide, 
methotrexate and fluorouracil) and trastuzumab at 
Fondazione IRCCS, Istituto Nazionale dei Tumori of 
Milan. Blood samples of these patients were collected at 
two time points during neoadjuvant treatment: pre, before 
any treatment; post, after AT cycles.
Eighteen buffy-coats of the “trastuzumab upfront 
in HER2-positive locally advanced breast cancer” 
(TRUP) cohort deriving from the recent prospective 
neoadjuvant study [16] were obtained from patients 
before any treatment. Patients were treated with one 
cycle of trastuzumab alone followed by 4 cycles of 
taxotere and trastuzumab. Tumor dimensions on post-
therapy day 21 were measured by FDG PET/CT scan. 
Pathological complete response (pCR) was defined as 
no residual invasive tumor or in situ carcinoma in the 
primary tumor and in the nodes. Human peripheral blood 
and tumor specimens were obtained at Fondazione IRCCS 
Istituto Nazionale dei Tumori of Milan and A.O. Istituti 
Ospitalieri di Cremona after written informed consent 
from patients in accordance with the Helsinki Declaration 
and after institutional approval from our ethics committee 
(Comitato Etico Indipendente, Fondazione IRCCS, Istituto 
Nazionale dei Tumori) for the conduct of the study.
Western blotting
Protein fractions were extracted from tumors 
grown in athymic mice and analyzed by Western blotting 
as described [39]. Antibodies used were: anti-vinculin 
(Sigma-Aldrich, St. Louis, MO, USA), anti-MICA and 
anti-ULBP2 (R&D Systems, Minneapolis, MN, USA).
RNA extraction and quantitative real-time PCR 
(qRT-PCR)
Total RNA was extracted from buffy-coats with 
Qiazol® (Qiagen) according to the manufacturer‘s 
instructions. cDNAs were reverse-transcribed from 1 
μg of total RNA in a 20-μl volume with SuperScript III 
(Invitrogen) using random-hexamer primers. qRT-PCR 
was performed using Applied Biosystem Taqman assays 
(CD16: Hs.04334165_m1, NKG2D: Hs.00183683_m1) 
on the ABI Prism 7900HT sequence detection system 
(Applied Biosystems, Foster City, CA, USA). NKG2D 
expression levels were calculated by the comparative 
Ct method using CD16 as reference gene and RNA 
obtained from a healthy donor buffy-coat as reference 
sample.
Flow cytometry
MDAMB361 and BT474 cells were exposed to 
docetaxel (100 nM) for 6 to 72 hours or left untreated, 
collected and incubated at 4°C with anti-MICA, -MICB, 
-ULBP1, -ULBP2 (R&D Systems), followed by 
incubation with anti-mouse Alexa Fluor 448-conjugated 
reagent (Invitrogen, Waltham, MA, USA). Samples were 
analyzed by gating on live cells using the FACSCanto 
system (Becton-Dickinson, San Jose, CA, USA) and BD 
FACSDiva™ software (BD Bioscience).
PBMCs isolated from patients or healthy 
donors were analyzed using monoclonal antibodies to 
human antigens, including PE-anti-CD16 (3G8, BD 
Bioscience), PECy5-anti-CD56 (B159, BD Bioscience), 
APC-eFluor780-anti-CD3 (SK7, eBioscence, San Diego, 
CA, USA), FITC-anti-CD69 (FN50, BD Bioscience) 
and APC-NKG2D (ON72, Beckman Coulter, Miami, 
FL, USA).
Total splenocytes or purified Gr1+ myeloid 
cells from mouse spleens were analyzed using mouse 
monoclonal antibodies, including PE-anti-CD49b (DX5, 
eBioscience), APC-anti-NKG2D (CX5, eBioscience), 
PE-anti-CD11 (MI/70, BD Bioscience), FITC-anti-Ly6G 
(1A8, Mylteni Biotec) and APC-anti-Ly6C (HK1.4, 
eBioscience). Samples were analyzed by gating on 
physical parameters using the FACSCanto II system 
(Becton-Dickinson) and FlowJo software (Tree Star Inc, 
San Carlos, CA, USA).
Cytotoxicity assays
Breast carcinoma cells were treated or not (controls) 
with docetaxel (100 nM) for 6, 12 or 72 hours and labeled 
with 100 μCi 51Cr (Perkin-Elmer, Waltham, MA, USA) 
for 1 hour at 37°C. After 3 washes with PBS-5% FBS, 
cells were co-incubated for 4 hours at 37°C with PBMCs 
isolated by density-gradient separation using Ficoll-
Paque PLUS (Amersham Biosciences, Piscataway, NJ, 
USA) from healthy donors (effector:target ratio 50:1) in 
200 μl RPMI 1640 complete medium (Gibco, Waltham, 
MA, USA) in triplicate 96-well U-bottomed plates in 
the presence of saturating concentrations of trastuzumab 
(4 μg/ml). NKG2D (1 μg/ml; R&D Systems) was used 
in blocking experiments. Radioactivity of the supernatant 
was measured with a Trilux Beta Scintillation Counter 
(Perkin-Elmer). Percent specific lysis was calculated as: 
100 × (experimental cpm – spontaneous cpm)/ (maximum 
cpm – spontaneous cpm).
ELISA assay
Soluble MICA and ULBP2 were quantified in 
breast carcinoma cell supernatants using DuoSet ELISA 
kits (R&D Systems), following the manufacturer’s 
instructions. Cell culture supernatants were collected 
at different time points after treatment with docetaxel 
and stored at -80°C until use. ELISA detection was 
performed using 100 μl of each supernatant. Soluble 
ligand quantification was normalized to the number 
of cells still present in culture as assessed by SRB 
colorimetric assay.
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Statistical analysis
Analyses were performed using GraphPad Prism 5 
(GraphPad Software). Differences between groups were 
determined by two-tailed Student’s t-test. Differences 
were considered significant at p < 0.05.
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